Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution
control group:Water for injection atomization inhalation combined with standard therapy
Sponsors
Harbin infectious diseases hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years old, both male and female; 2. The eligible subjects (male and female) with fertility must agree to take effective contraceptive measures from the beginning of self-sufficiency with their partners to 6 months after drug withdrawal; 3. Novel coronavirus pneumonia diagnosis novel coronavirus pneumonia novel coronavirus pneumonia diagnosis and treatment plan (latest edition) is confirmed; 4. Drugs without chloroquine and its derivatives within three months; 5. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with allergic history to 4-aminoquinoline (such as chloroquine, hydroxychloroquine, piperaquine, aminophenquine, etc.) and similar drugs (such as primaquine, etc.) were identified; 2. Patients with blood system diseases; 3. Patients with hearing impairment; 4. Patients with known severe liver disease, basic disease of liver cirrhosis or ALT / AST increased more than 2 times of the upper limit of normal; 5. Patients who drink alcohol or are taking hepatotoxic drugs; 6. Patients with known impairment of renal function (estimated glomerular filtration rate [EGFR] =450ms; 10. Patients with uncorrected hypokalemia and hypomagnesemia; 11. Patients with known retinopathy, fundus disease and macular disease; 12. Patients known to have mental illness; 13. Patients with pancreatitis; 14. Female patients in pregnancy, childbearing age with positive pregnancy test or lactation; 15. Taking drugs that affect drug absorption, metabolism and excretion, can prolong QTc interval, can affect drug efficacy or increase adverse reactions; 16. Patients with a history of malignancy in the last 5 years; 17. Patients with skin diseases (including skin rash, dermatitis, psoriasis); 18. The novel coronavirus pneumonia diagnosis and treatment scheme (latest edition) has been adopted in the standard treatment of 2 and 2 or more antiviral drugs; 19. The researchers judged that it was not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sampling interval at least 1 day); | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of severe cases;Length of stay;Oxygen saturation;Mechanical ventilation time; | — |
Countries
China
Contacts
Public ContactJing Xu
Harbin Peiyou Jiandi Biotechnology Co., Ltd
Outcome results
None listed